MicroRNAs (miRNAs) have been proven to be important oncogenes and tumor suppressors in wide range of cancers, including renal cell carcinoma (RCC). In our study, we evaluated miRNA-429 as potential diagnostic/prognostic biomarker in 172 clear cell RCC patients and as a potential regulator of epithelial-mesenchymal transition (EMT) in vitro. We demonstrated that miR-429 is down-regulated in tumor tissue samples (P < 0.0001) and is significantly associated with cancer metastasis (P < 0.0001), shorter disease-free (P = 0.0105), and overall survival (P = 0.0020). In addition, ectopic expression of miR-429 in 786-0 RCC cells followed by TGF-β treatment led to increase in the levels of E-cadherin expression (P < 0.0001) and suppression of cellular migration (P < 0.0001) in comparison to TGF-β-treated controls. Taken together, our findings suggest that miR-429 may serve as promising diagnostic and prognostic biomarker in RCC patients. We further suggest that miR-429 has a capacity to inhibit loss of E-cadherin in RCC cells undergoing EMT and consequently attenuate their motility.

Central European Institute of Technology Masaryk University University Campus Bohunice Building A35 Room 217 Kamenice 5 625 00 Brno Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Urologic Oncology Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Urology University Hospital Brno and Masaryk University Brno Czech Republic

Zobrazit více v PubMed

J Hum Genet. 2013 Aug;58(8):508-16 PubMed

J Biomed Sci. 2015 Jan 23;22:9 PubMed

Mol Cell Biochem. 2014 May;390(1-2):19-30 PubMed

Cancer Res. 2008 Oct 1;68(19):7846-54 PubMed

Mol Cell. 2008 May 23;30(4):460-71 PubMed

Acta Biochim Biophys Sin (Shanghai). 2009 Aug;41(8):648-56 PubMed

Mol Cancer Res. 2015 Mar;13(3):565-74 PubMed

J Clin Med. 2015 Aug 21;4(8):1651-67 PubMed

J Biol Chem. 2008 May 30;283(22):14910-4 PubMed

Cell Death Dis. 2013 Mar 14;4:e541 PubMed

Cancer Biomark. 2010;9(1-6):461-73 PubMed

J Clin Oncol. 2015 Dec 10;33(35):4151-7 PubMed

DNA Cell Biol. 2015 Jun;34(6):429-36 PubMed

Trends Cell Biol. 2014 Mar;24(3):153-60 PubMed

Oncotarget. 2015 Sep 29;6(29):27083-96 PubMed

Mol Cancer Res. 2010 Sep;8(9):1207-16 PubMed

N Engl J Med. 2016 Jan 14;374(2):135-45 PubMed

Biomed Pharmacother. 2016 May;80:311-21 PubMed

PLoS One. 2013 Sep 04;8(9):e73436 PubMed

Cancer Lett. 2015 Aug 1;364(1):33-43 PubMed

Biomark Res. 2015 Mar 02;3:5 PubMed

Oncotarget. 2016 May 3;7(18):26593-603 PubMed

Oncotarget. 2015 Jun 20;6(17):15222-34 PubMed

Biomed Pharmacother. 2013 Jun;67(5):381-6 PubMed

J Biol Chem. 2012 Feb 17;287(8):5819-32 PubMed

Oncotarget. 2016 Jun 14;7(24):37250-37259 PubMed

PLoS One. 2014 Feb 11;9(2):e87780 PubMed

Acta Histochem. 2016 Mar;118(2):144-51 PubMed

Mol Med Rep. 2016 Apr;13(4):3236-42 PubMed